drugset / Trial / NCT07706907
An Expanded Access Program for SYN023 in Rabies Treatment
Summary
This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative therapies.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mazorelvimab | Monoclonal antibody | — | — |
| Subject | Zamerovimab | Monoclonal antibody | — | — |